• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

FDA ready to set standards for contrast sensitivity testing

Article

The FDA soon will approve standards for contrast sensitivity testing in clinical trials. The approval is a step that will not only make the administration of this test easier for ophthalmologists but its comparison with clinical trial data and other testing centers simpler and more valuable as well.

Related Videos
Related Content
Verana Health launches its Qdata Thyroid Eye Disease module

Verana Health launches its Qdata Thyroid Eye Disease module

Article
Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures

(EyePod) From idea to impact: Navigating ophthalmic innovation

Podcast
Phoenix-Micron Inc and ArtiKode Intelligence team up to enhance OCT imaging with AI

Phoenix-Micron Inc and ArtiKode Intelligence team up to enhance OCT imaging with AI

Article
EyePod: Modifier Gene Therapy: What is it?

EyePod: Modifier Gene Therapy: What is it?

Podcast
Orbis, FundamentalVR team up to target training

Orbis, FundamentalVR team up to target training

Article
Ocugen completes dosing of subjects with geographic atrophy in Cohort 2 of Phase 1/2 ArMaDa clinical trial of OCU410

Ocugen completes dosing of subjects with geographic atrophy in Cohort 2 of Phase 1/2 ArMaDa clinical trial of OCU410

Article
© 2024 MJH Life Sciences

All rights reserved.